US HB383 | 2023-2024 | 118th Congress

Status

Spectrum: Partisan Bill (Republican 27-0)
Status: Introduced on January 17 2023 - 25% progression
Action: 2023-01-27 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]

Summary

To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

Sponsors


History

DateChamberAction
2023-01-27HouseReferred to the Subcommittee on Health.
2023-01-17HouseReferred to the House Committee on Energy and Commerce.
2023-01-17HouseIntroduced in House

Same As/Similar To

HB4368 (Related) 2023-09-28 - Motion to reconsider laid on the table Agreed to without objection.

Subjects


US Congress State Sources


Bill Comments

feedback